Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

(2015) Hatem H. Soliman et al.   Oncotarget

Use of Statins and the Risk of Death in Patients With Prostate Cancer

(2013) Oriana Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of Indoleamine 2,3-Dioxygenase and Correlation With Pathological Malignancy in Gliomas

(2013) Kentaro Mitsuka et al.   NEUROSURGERY

Targeting Tregs in Malignant Brain Cancer: Overcoming IDO

(2013) Derek A. Wainwright et al.   Frontiers in Immunology

IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival

(2012) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

(2011) J. Godin-Ethier et al.   CLINICAL CANCER RESEARCH

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

(2011) Christiane A. Opitz et al.   NATURE

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

(2010) X. Liu et al.   BLOOD

Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma

(2009) Hiroshi Urakawa et al.   CLINICAL & EXPERIMENTAL METASTASIS

Overexpression of Indoleamine 2,3-Dioxygenase in Human Endometrial Carcinoma Cells Induces Rapid Tumor Growth in a Mouse Xenograft Model

(2008) N. Yoshida et al.   CLINICAL CANCER RESEARCH

Cigarette smoke extract induces thymic stromal lymphopoietin expression, leading to TH2-type immune responses and airway inflammation

(2008) Yuki Nakamura et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Immune escape as a fundamental trait of cancer: focus on IDO

(2008) G C Prendergast   ONCOGENE